Product Information
BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.2216 per EA under NDC 62559041601. Its NADAC has been published 191 times since Feb 8, 2023.
FDA first approved this application on Feb 11, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB
Benazepril Hydrochloride and HydrochlorothiazideStrength
20; 12.5 mg/1; mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559041601
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076342FDA Approved
2/11/2004
TE Code
AB
On Market Since
11/7/2022
Pharmacological Classes
Price Statistics
The NADAC for BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has been published 191 times since Feb 8, 2023, and over the history we have for it it has declined 52.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2216 per EA |
|---|---|
| All-time high | $0.5779 (Mar 15, 2023) |
| All-time low | $0.1503 (Nov 20, 2024) |
| 52-week high | $0.2349 |
| 52-week low | $0.1742 |
| Median price | $0.2492 |
| Average price | $0.2902 |
| Largest weekly change | +56.5% (Oct 18, 2023) |
| Weeks tracked | 191 |
| Tracking since | Feb 8, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Benazepril Hydrochloride and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB, manufactured by ANI Pharmaceuticals, Inc., is $0.2216 per EA (NDC 62559041601), effective Sep 30, 2026.
How has the price of BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has declined 52.4%. It has been tracked across 191 weekly CMS publications since Feb 8, 2023.
What are the highest and lowest recorded NADAC prices for BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
Since Feb 8, 2023, the NADAC for BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has ranged from a low of $0.1503 (Nov 20, 2024) to a high of $0.5779 (Mar 15, 2023), with a median of $0.2492 per EA.
Are there cheaper alternatives to BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB (NDC 62559041601) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.